carotenoids
发表于 2025-3-25 05:07:06
http://reply.papertrans.cn/55/5448/544771/544771_21.png
注射器
发表于 2025-3-25 11:19:55
http://reply.papertrans.cn/55/5448/544771/544771_22.png
凶猛
发表于 2025-3-25 11:56:06
Michael Olsson,Dirk Piekenbrock, allows detailed profiling of oligosaccharides attached to each glycosylation site. The current CDG concept covers disorders affecting other types of glycosylation, among which mucin-type .-glycosylation is assessed by MALDI MS of serum apolipoprotein C-III without any purification steps.
perimenopause
发表于 2025-3-25 16:57:32
http://reply.papertrans.cn/55/5448/544771/544771_24.png
脆弱么
发表于 2025-3-25 20:46:33
http://reply.papertrans.cn/55/5448/544771/544771_25.png
creatine-kinase
发表于 2025-3-26 00:09:04
Michael Olsson,Dirk Piekenbrock the form of a comprehensive and strictly systematic survey. The texts are furnished by 2.670 figures, chemical structures and reaction schemes (including more than 12.000 individual chemical reactions), and more than 9.000 references.978-3-642-63213-6978-3-642-56874-9
MARS
发表于 2025-3-26 07:47:30
Michael Olsson,Dirk Piekenbrock the form of a comprehensive and strictly systematic survey. The texts are furnished by 2.670 figures, chemical structures and reaction schemes (including more than 12.000 individual chemical reactions), and more than 9.000 references.978-3-642-63213-6978-3-642-56874-9
安定
发表于 2025-3-26 12:24:39
Michael Olsson,Dirk Piekenbrockve been reported: One is the discovery of the new binding sites in various Siglec molecules different than the conventional binding site; the other is the finding of the mucin-type ligands as a natural counter-receptor of Siglec7. These new features thus led us to overview the new binding sites of S
Limousine
发表于 2025-3-26 14:56:02
http://reply.papertrans.cn/55/5448/544771/544771_29.png
捐助
发表于 2025-3-26 18:37:09
http://reply.papertrans.cn/55/5448/544771/544771_30.png